AbbVie Dermatitis Drug Met Primary Trial Endpoints

The investigational antibody zumilokibart successfully reached skin clearance goals in a phase 2 clinical trial.

Updated on Sept. 30, 2026 in Asthma

AbbVie Dermatitis Drug Met Primary Trial Endpoints

Live Poll

Do you trust pharmaceutical companies to balance drug convenience with patient safety in clinical trials?

AbbVie announced that its investigational monoclonal antibody zumilokibart achieved a 75 percent reduction in EASI scores in a phase 2 atopic dermatitis trial. The company has selected a mid-dose regimen of the drug for advancement into phase 3 clinical development.

Why it matters

This development signals potential for a new long-acting treatment option for moderate to severe atopic dermatitis, addressing skin clearance and itch reduction. AbbVie will now assess dosing intervals for the drug in the next stage of testing.

The APEX Part B trial involved 346 adults, with the primary endpoint defined as a 75 percent reduction from baseline in EASI scores at 16 weeks. The investigational drug, which targets IL-13, has an estimated half-life of 77 days.

The players

AbbVie

AbbVie is a global research-based biopharmaceutical company that develops therapies for complex and chronic diseases.

The details

The trial randomized participants to receive one of three dose regimens or a placebo to measure skin clearance and itch reduction over a 16-week induction period. Mid- and high-dose regimens demonstrated superior performance compared to placebo on EASI-90 and EASI-100 endpoints, with reported side effects including nasopharyngitis and headache.

Week 1: Mid-dose regimen achieved reductions in EASI scores.
Week 2: Mid-dose regimen achieved reduction in I-NRS itch scores.
Week 16: Trial measured the primary EASI-75 response endpoint.
September 30, 2026: Full study findings were presented at the EADV Congress.

The Big Picture

This trial follows a pattern set by research into the IL-13 inhibition pathway for atopic dermatitis by testing a humanized monoclonal antibody designed for skin clearance. It extends existing evidence for this biological mechanism while aiming to differentiate the treatment through extended dosing intervals.

Patients suffering from moderate to severe atopic dermatitis may eventually have access to a new long-acting treatment option that targets underlying inflammation. However, the medication is not yet approved by any regulatory authority and is currently limited to clinical trial environments.

The takeaway

Advancements in long-acting monoclonal antibodies could eventually reduce the frequency of treatments for those with chronic inflammatory skin conditions. Patients should consult with dermatologists regarding standard-of-care options while awaiting further regulatory progress on new investigational drugs.